TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19256728

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychiatric Music Therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future Music Therapy Research
Number of subjects: 0
Study: 17580544

Group type: EXPERIMENTAL
Intervention: Ultrasound treatment applied on lumbar paravertebral muscle
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (machine not switched on)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ultrasound treatment
Number of subjects: 31
Study: 14694916

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (5 L/min)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Air (5 L/min)
Number of subjects: 33
Study: 10869641

Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine (2 mg, dose-optimization schedule)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine (5 mg, fixed-dose)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine (6 mg, fixed-dose)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine (all doses)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 569
Study: 9186252

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) controlled release (CR) 400 mg initial administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) controlled release (CR) 400 mg twice daily for 1 month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (young healthy volunteers)
Number of subjects: 0
Study: 1607415

Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream, applied twice daily for 1 week
Number of subjects: 159

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 159
Study: 4026357

Group type: EXPERIMENTAL
Intervention: Frusemide (1 mg/kg) administered intravenously at approximately 24 hour intervals for three doses.
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no frusemide).
Number of subjects: 85
Study: 30261471

Group type: EXPERIMENTAL
Intervention: School-based prevention program (JuvenTUM 3)
Number of subjects: 434
Study: 26811189

Group type: EXPERIMENTAL
Intervention: Regional blocks (bilateral CNV2 and CNV3 divisions of the trigeminal nerve) with local anaesthesia containing 1/100,000 epinephrine and 10 ml 0.5% levobupivacaine.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Regional blocks (bilateral CNV2 and CNV3 divisions of the trigeminal nerve).
Number of subjects: 50

Group type: COMPARATOR
Intervention: No regional blocks (group A).
Number of subjects: 50
Study: 24305905

Group type: EXPERIMENTAL
Intervention: Peer support workers (PSWs) trained over 12 weekly, 1-day sessions from April to July 2010.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer support workers (PSWs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervision and support provided by a peer support coordinator and a training facilitator.
Number of subjects: 0
Study: 22218245

Group type: EXPERIMENTAL
Intervention: Topical ofloxacin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 5% Povidone Iodine (PI) instillation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Manual SICS
Number of subjects: 300

Group type: COMPARATOR
Intervention: Phacoemulsification (Phaco)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Well-controlled diabetics
Number of subjects: 300

Group type: COMPARATOR
Intervention: Non-diabetics
Number of subjects: 300
Study: 20603858

Group type: EXPERIMENTAL
Intervention: Prophylactic placement of polypropylene mesh in the preperitoneal plane
Number of subjects: 85

Group type: COMPARATOR
Intervention: Routine abdominal mass closure after AAA repair (Control)
Number of subjects: 85
Study: 18390395

Group type: EXPERIMENTAL
Intervention: Oral intubation (OI)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Nasal intubation (NI)
Number of subjects: 71
Study: 16231265

Group type: EXPERIMENTAL
Intervention: 28-day regimen of antiretroviral therapy and counseling
Number of subjects: 877
Study: 12657405

Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil anesthesia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane-remifentanil anesthesia
Number of subjects: 40
Study: 10410476

Group type: EXPERIMENTAL
Intervention: Membrane stripping
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (no membrane stripping)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study: 7755228

Group type: EXPERIMENTAL
Intervention: 50 g of alcohol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2077981

Group type: EXPERIMENTAL
Intervention: Midazolam sedation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Local anesthesia alone
Number of subjects: 32
Study: 537567

Group type: EXPERIMENTAL
Intervention: Flupirtine (p.o.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pentazocin (p.o.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (p.o.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Flupirtine (i.v.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pentazocin (i.v.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (i.v.)
Number of subjects: 6
Study: 30770639

Group type: EXPERIMENTAL
Intervention: 3D-printing group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 30149668

Group type: EXPERIMENTAL
Intervention: Theory-informed school-based intervention consisting of ten sessions based on social cognitive theory and the social influences approach.
Number of subjects: 1279

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 1279

Group type: EXPERIMENTAL
Intervention: Theory-informed school-based intervention.
Number of subjects: 1279
Study: 27352494

Group type: EXPERIMENTAL
Intervention: Acupoint implantation at Fengchi (GB 20), Taiyang (EX‐HN 5), Waiguan (TE 5), Yanglingquan (GB 34), once every 2 weeks for 4 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Electroacupuncture (EA) at the same acupoints as the implantation group, applied once every two days for 4 weeks.
Number of subjects: 60
Study: 24560764

Group type: EXPERIMENTAL
Intervention: Whole brain radiation therapy (WBRT) after local treatment of melanoma brain metastases
Number of subjects: 77
Study: 21790621

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (RBCs if Hb concentration was 70 g/L or less intraoperatively during CPB and 75 g/L or less postoperatively)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (RBCs if Hb concentration was 95 g/L or less during CPB and less than 100 g/L postoperatively)
Number of subjects: 50
Study: 19896194

Group type: EXPERIMENTAL
Intervention: Short-wavelength automated perimetry (SWAP)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Standard automated perimetry (SAP)
Number of subjects: 416
Study: 17981847

Group type: EXPERIMENTAL
Intervention: Intensive therapy (5 hours/week for 12 weeks)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard therapy (2 hours/week for 12 weeks)
Number of subjects: 121

Group type: COMPARATOR
Intervention: NHS group (2 hours/week for 12 weeks)
Number of subjects: 121
Study: 15222004

Group type: EXPERIMENTAL
Intervention: 100 mg/m(2) of docetaxel every 14 days with lenograstim
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 100 mg/m(2) of docetaxel every 10 days with lenograstim
Number of subjects: 39

Group type: COMPARATOR
Intervention: 100 mg/m(2) of docetaxel every 21 days without lenograstim
Number of subjects: 39

Group type: COMPARATOR
Intervention: 100 mg/m(2) of docetaxel every 18 days with lenograstim
Number of subjects: 39
Study: 12122788

Group type: EXPERIMENTAL
Intervention: Creme
Number of subjects: 12

Group type: COMPARATOR
Intervention: Powder
Number of subjects: 12
Study: 9630389

Group type: EXPERIMENTAL
Intervention: Vinegar (acetic acid) added to a starchy meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: White bread reference meal (control)
Number of subjects: 10
Study: 11271340

Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 49

Group type: COMPARATOR
Intervention: Cyclosporin (CyA)
Number of subjects: 49

Group type: COMPARATOR
Intervention: CyA
Number of subjects: 49
Study: 3184026

Group type: EXPERIMENTAL
Intervention: COMMUNITY-based dental delivery system
Number of subjects: 725

Group type: COMPARATOR
Intervention: SCHOOL-based dental delivery system
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Both groups (COMMUNITY and SCHOOL)
Number of subjects: 725
Study: 31596648

Group type: EXPERIMENTAL
Intervention: Ria Treatment Platform (RTP)
Number of subjects: 77
Study: 29504187

Group type: EXPERIMENTAL
Intervention: AZ11760788
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AZ12048189
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AZ12099548
Number of subjects: 36
Study: 27599039

Group type: EXPERIMENTAL
Intervention: IMM-101 (10 mg/ml intradermally) + GEM (1000 mg/m² intravenously)
Number of subjects: 110

Group type: COMPARATOR
Intervention: GEM alone
Number of subjects: 110
Study: 25409371

Group type: EXPERIMENTAL
Intervention: Early nasoenteric tube feeding within 24 hours after randomization
Number of subjects: 208

Group type: COMPARATOR
Intervention: Oral diet initiated 72 hours after presentation (on-demand group)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Early nasoenteric tube feeding
Number of subjects: 208
Study: 22520136

Group type: EXPERIMENTAL
Intervention: HRV (Rotarix) 2 doses (10 and 14 weeks)
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: HRV (Rotarix) 3 doses (6, 10 and 14 weeks)
Number of subjects: 1339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1339
Study: 20656094

Group type: EXPERIMENTAL
Intervention: Soy intervention
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 163
Study: 18829392

Group type: EXPERIMENTAL
Intervention: MLN0002 2.0 mg/kg
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: MLN0002 0.5 mg/kg
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 15975977

Group type: EXPERIMENTAL
Intervention: Short-Duration Intermittent Hypoxia (SDIH, 12% O2 for 1 hour with 5 min normoxia)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Long-Duration Intermittent Hypoxia (LDIH, 30 min of 12% O2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both SDIH and LDIH
Number of subjects: 18
Study: 11834958

Group type: EXPERIMENTAL
Intervention: HSV2 positive at baseline
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Acquiring HSV2 infection during follow‐up
Number of subjects: 763
Study: 8828788

Group type: EXPERIMENTAL
Intervention: Duraflo II heparin coated equipment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Uncoated equipment (control group)
Number of subjects: 24
Study: 2073038

Group type: EXPERIMENTAL
Intervention: Echinaceae (84 to 112 mg/day) and Sabalae (78 to 104 mg/day) extracts (URGENIN: 90 to 120 drops/day) for a mean time of 77 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (90 to 120 drops/day) for a mean time of 52 days
Number of subjects: 30
Study: 7361704

Group type: EXPERIMENTAL
Intervention: 5 mg thiamin hydrochloride
Number of subjects: 19

Group type: COMPARATOR
Intervention: Thiamin placebo
Number of subjects: 19
Study: 30665397

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 135

Group type: COMPARATOR
Intervention: Low-fidelity simulation
Number of subjects: 135
Study: 28084062

Group type: EXPERIMENTAL
Intervention: Progressive elastic band resistance training for 12 weeks (3 times per week)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group received a 40-minute lesson about the exercise concept
Number of subjects: 35
Study: 25633731

Group type: EXPERIMENTAL
Intervention: Lateral sentinel lymph node biopsy (LSLNB)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 283
Study: 25543425

Group type: EXPERIMENTAL
Intervention: Dog days moxibustion plaster therapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Beclometasone dipropionate aqueous nasal spray
Number of subjects: 168
Study: 20938662

Group type: EXPERIMENTAL
Intervention: R-CHOP treatment in IDO-positive DLBCL
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: R-CHOP treatment in IDO-negative DLBCL
Number of subjects: 119
Study: 19300380

Group type: EXPERIMENTAL
Intervention: Epidural Steroids
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 17329690

Group type: EXPERIMENTAL
Intervention: Protocol A (9 seconds)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Protocol B (12 seconds)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Protocol C (15 seconds)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Protocol D (18 seconds)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Protocol E (21 seconds)
Number of subjects: 192
Study: 15479169

Group type: EXPERIMENTAL
Intervention: bofu-tsusho-san (BF)
Number of subjects: 81

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 81
Study: 11398878

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10517729

Group type: EXPERIMENTAL
Intervention: Enoxaparin (initial 30 mg intravenous bolus followed by 1.0 mg/kg every 12 hours; outpatient phase: 40 mg for patients <65 kg and 60 mg for patients ≥65 kg)
Number of subjects: 3910

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) for ≥3 days followed by subcutaneous placebo injections
Number of subjects: 3910

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 3910

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3910
Study: 8584300

Group type: EXPERIMENTAL
Intervention: RGO‐II hybrid orthosis
Number of subjects: 21
Study: 2127076

Group type: EXPERIMENTAL
Intervention: Calcium intake of 2.5 mmol/kg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Calcium intake of 3.75 mmol/kg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Calcium intake of 5 mmol/kg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Phosphate intake of 2.5 mmol/kg/day
Number of subjects: 24
Study: 363977

Group type: EXPERIMENTAL
Intervention: 50 mg of clomipramine given three times a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: 150 mg of clomipramine in a single bedtime dosage
Number of subjects: 0
Study: 30531560

Group type: EXPERIMENTAL
Intervention: Patient-centered poster
Number of subjects: 990

Group type: COMPARATOR
Intervention: CDC poster
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Both posters
Number of subjects: 990
Study: 28681205

Group type: EXPERIMENTAL
Intervention: FM33.3 diet (33.3% fishmeal replaced by soy protein concentrate with 0.4% GMP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FM66.7 diet (66.7% fishmeal replaced by soy protein concentrate with 0.4% GMP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FM100 diet (100% fishmeal replaced by soy protein concentrate with 0.4% GMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FM0 diet (control diet with 0% fishmeal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FM diet groups (FM33.3 and FM66.7)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FM diet groups with increasing FM replacement by SPC with GMP supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing FM replacement level by SPC
Number of subjects: 0
Study: 25897757

Group type: EXPERIMENTAL
Intervention: Aftercare coordination by phone (6 phone contacts at intervals of 2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aftercare coordination by phone
Number of subjects: 0
Study: 24029539

Group type: EXPERIMENTAL
Intervention: Long-term group therapy (80 weekly, 90 min sessions)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Short-term group therapy (20 weekly, 90 min sessions)
Number of subjects: 167
Study: 21890888

Group type: EXPERIMENTAL
Intervention: rFVIIa (10 μg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rFVIIa (20 μg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rFVIIa (10 and 20 μg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: rFVIIa (not specified dosage)
Number of subjects: 40
Study: 19278128

Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex (6 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17184374

Group type: EXPERIMENTAL
Intervention: Repositioning every 2 hours in a lateral position and 4 hours in a supine position (experimental group)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Repositioning every 4 hours (control group)
Number of subjects: 235
Study: 15250816

Group type: EXPERIMENTAL
Intervention: Manualized therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychotherapy process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empirical validation of change processes
Number of subjects: 0
Study: 11930400

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study: 9776794

Group type: EXPERIMENTAL
Intervention: Assessment of protein nutritional status (albumin and protein catabolic rate)
Number of subjects: 298
Study: 8845601

Group type: EXPERIMENTAL
Intervention: Calcium augmentation (1700 mg)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) with dietary calcium augmentation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 2521362

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: PTA
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Both groups (Surgery and PTA)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Surgery after unsuccessful PTA
Number of subjects: 263
Study: 1101946

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2-Br-alpha-ergocryptine)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Chlorotrianisene
Number of subjects: 38
Study: 31534042

Group type: EXPERIMENTAL
Intervention: Pandoravirus dulcis and Pandoravirus quercus
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparative genomics of Pandoraviridae
Number of subjects: 10
Study: 28119138

Group type: EXPERIMENTAL
Intervention: Kg‐Free intervention (10 weekly group sessions plus 2 booster fortnightly sessions, 2h30 each)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 73
Study: 25938187

Group type: EXPERIMENTAL
Intervention: Mindfulness and acceptance-based group therapy (MAGT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy (CBGT)
Number of subjects: 69
Study: 23748166

Group type: EXPERIMENTAL
Intervention: Statin therapy for 8 months
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP) levels
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: hs-CRP level
Number of subjects: 119
Study: 22002336

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Irbesartan (300 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Aliskiren (300 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Irbesartan (300 mg) after 14 days
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Aliskiren (300 mg) after 14 days
Number of subjects: 43
Study: 19426749

Group type: EXPERIMENTAL
Intervention: Central fixation point (FP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surrounding fixation points (FPs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No fixation point (FP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contrast discrimination task
Number of subjects: 0
Study: 16466609

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 0.5 mg/2 mL bid
Number of subjects: 82

Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG) 20 mg/2 mL tid
Number of subjects: 82
Study: 15385010

Group type: EXPERIMENTAL
Intervention: Microcuff pediatric tracheal tube (HVLP cuff)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mallinckrodt Hi-Contour P
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rüschelit Super Safety Clear
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sheridan CF
Number of subjects: 80
Study: 11751715

Group type: EXPERIMENTAL
Intervention: Omapatrilat
Number of subjects: 61

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 61
Study: 9240180

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (weekly counselling 4-9 weeks after surgery)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 50
Study: 8215266

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ticarcillin-clavulanate
Number of subjects: 0
Study: 2884059

Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2% carteolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.6% metipranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31702409

Group type: EXPERIMENTAL
Intervention: CopeSmart mobile app used over a 4-week period
Number of subjects: 560

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 560
Study: 29914940

Group type: EXPERIMENTAL
Intervention: IMT+PR (n=110)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Sham-IMT+PR (n=109)
Number of subjects: 219
Study: 27938777

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention (maximum reward = $430)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Non-contingent yoked controls (NCYC)
Number of subjects: 140
Study: 26700834

Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 203

Group type: COMPARATOR
Intervention: IRA-only revascularization
Number of subjects: 203
Study: 23123181

Group type: EXPERIMENTAL
Intervention: Movement of both hands
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Motor imagery of the same movement
Number of subjects: 22

Group type: COMPARATOR
Intervention: Instruction to hold both hands still
Number of subjects: 22
Study: 22109763

Group type: EXPERIMENTAL
Intervention: Chemical ear peeling (CEP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Antibiotic/steroid treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chemical ear peeling (CEP) in chronic otitis externa exacerbation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chemical ear peeling (CEP) in acute otitis externa
Number of subjects: 50